In December 8th, China's first anti COVID-19 drug, the specific drug of the combination of the anti - mAb / romicwell monoclonal antibody, was approved by the China pharmaceutical regulatory commission. This marks the first official research that China has developed and proved effective anti COVID-19 antibody. Zhang Linqi, Professor of Tsinghua University School of medicine and director of the global health and infectious diseases research center, is the leader of this R & D team.

Clinical trial data show that the specific drug can reduce the hospitalization rate and mortality of 80% of high-risk Xinguan outpatients, and its main role is treatment. At the same time, the antibody can remain in the human body for 9 to 12 months, which also plays a certain role in preventing infection. This is the best treatment data available worldwide for COVID-19 specific drugs.